logo
Family files for release in lawsuit considered first involving children challenging arrests at court

Family files for release in lawsuit considered first involving children challenging arrests at court

Washington Post4 hours ago

A mother and her two young kids are fighting for their release from a Texas immigration detention center in what is believed to be the first lawsuit involving children challenging the Trump administration's policy on immigrant arrests at courthouses.
The lawsuit filed Tuesday argues that the family's arrests after fleeing Honduras and entering the U.S. legally using a Biden-era appointment app violate the family's Fourth Amendment right to be free from unreasonable searches and seizure and their Fifth Amendment right to due process.
'The big picture is that the executive branch cannot seize people, arrest people, detain people indefinitely when they are complying with exactly what our government has required of them,' said Columbia Law School professor Elora Mukherjee, one of the lawyers representing the family.
The Department of Homeland Security did not immediately respond to an email requesting comment.
Starting in May, the country has seen large-scale arrests in which asylum-seekers appearing at routine court hearings have been arrested outside courtrooms as part of the White House's mass deportation effort. In many cases, a judge will grant a government lawyer's request to dismiss deportation proceedings and then U.S. Immigration and Customs Enforcement officers will arrest the person and place them on 'expedited removal,' a fast track to deportation.
Mukherjee said this is the first lawsuit filed on behalf of children to challenge the ICE courthouse arrest policy.
There have been other similar lawsuits, such as in New York, where a federal judge ruled earlier this month that federal immigration authorities can't make civil arrests at the state's courthouses or arrest anyone going there for a proceeding.
The Texas lawsuit was filed using initials for the children and 'Ms. Z' for the mother. Their identities have not been released because of concerns for the family's safety.
As the family has been held for a month in the Dilley Immigration Processing Center , the mother has watched her 6-year-old son's health decline, Mukherjee said. He recently underwent chemotherapy treatment for leukemia and because of his arrest missed his check-in doctor's appointment, Mukherjee said. In the weeks since, he has lost his appetite.
'He's easily bruising. He has bone pain. He looks pale,' Mukherjee said. 'His mom is terrified that these are symptoms that his leukemia situation might be deteriorating.'
The mother, son and 9-year-old daughter fled Honduras in October 2024 due to death threats, according to the lawsuit. They entered the U.S. using the CBP One app and were paroled into the country by the Department of Homeland Security, which determined they didn't pose a danger to the community, Mukherjee said. They were told to appear at a Los Angeles immigration court May 29.
President Donald Trump ended CBP One for new entrants on his first day in office after more than 900,000 people had been allowed in the country using the app since it was expanded to include migrants in January 2023.
During the family's hearing, the mother tried to explain to the judge that they wished to continue their cases for asylum, Mukherjee said. Homeland Security moved to dismiss their cases, and the judge immediately granted that motion.
When they stepped out of the courtroom, they found men in civilian clothing believed to be ICE agents who arrested the family, Mukherjee said. They were transported to an immigrant processing center in Los Angeles, where they spent about 11 hours and were each only given an apple, a small packet of cookies, a juice box and water.
At one point, an officer near the boy lifted his shirt, revealing his gun. The boy urinated on himself and was left in wet clothing until the next morning, Mukherjee said.
They were later taken to the processing center, where they have been held ever since.
'The family is suffering in this immigration detention center,' she said. 'The kids are crying every night. They're praying to God for their release from this detention center.'
Their lawyers have filed an appeal of the immigration judge's May decision, but they're at risk of being deported within days because the government says they are subjected to expedited removal, Mukherjee said.
The arrests of the family were illegal and unjustified, said Kate Gibson Kumar, an attorney for the Texas Civil Rights project who is also representing the family.
She said the government had already decided when they first entered the country that the family didn't need to be detained.
'The essential question in our case is, when you have these families who are doing everything right, especially with young children, should there be some protection there?' Gibson Kumar said. 'We say 'yes.''
___
Associated Press reporter Nadia Lathan in Austin, Texas, contributed to this report.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AAD Updates AD Guidelines With Four New Treatment Picks
AAD Updates AD Guidelines With Four New Treatment Picks

Medscape

time39 minutes ago

  • Medscape

AAD Updates AD Guidelines With Four New Treatment Picks

The American Academy of Dermatology (AAD) recently issued a focused update to its guidelines on the management of atopic dermatitis (AD) in adults, strongly recommending four recently approved therapies: tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab (in combination with topical therapy). These additions reflect high-certainty evidence supporting both efficacy and safety, according to the workgroup's systematic review published in the Journal of the American Academy of Dermatology . Robert Sidbury, MD Asked to comment on the updates, one of the authors, Robert Sidbury, MD, cochair of the guideline committee and chief of dermatology at Seattle Children's Hospital, Seattle, called the rapid need for a guideline update 'a reflection of the extraordinary progress in AD care that is ongoing and is indeed revolutionizing care.' Having 'two new nonsteroidal topical therapies is quite significant,' he added in an interview with Medscape Dermatology . 'Patients have long been dissatisfied with topical options, which have been shackled by safety concerns, some real, some not, and intolerance, such as application site stinging.' The update comes just over a year after the release of AAD's 2023-2024 adult AD guidelines on treatment with topical and systemic therapies, underscoring the rapid pace of therapeutic development for AD. The update was initiated following the FDA approval of multiple new therapies and newly published high-certainty evidence supporting their use, prompting the AAD to incorporate this data into its existing guidance, according to the authors. Strong Recommendations for Four New Agents The guideline workgroup applied the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework to assess new data and formulate treatment recommendations. According to the authors, all four therapies received 'strong' recommendations based on high-certainty evidence: Tapinarof cream 1% : A nonsteroidal aryl hydrocarbon receptor agonist approved in 2024 for moderate to severe AD. In four trials (n = 1169), once-daily use over 8-12 weeks resulted in statistically and clinically significant improvements in investigator's global assessment (IGA), eczema area and severity index (EASI)-75, and itch scores. : A nonsteroidal aryl hydrocarbon receptor agonist approved in 2024 for moderate to severe AD. In four trials (n = 1169), once-daily use over 8-12 weeks resulted in statistically and clinically significant improvements in investigator's global assessment (IGA), eczema area and severity index (EASI)-75, and itch scores. Roflumilast cream 0.15% : A phosphodiesterase-4 inhibitor approved in 2024 for mild to moderate AD. Clinical trials (n = 1427) demonstrated significant improvements in IGA and EASI-75 after 4 weeks. : A phosphodiesterase-4 inhibitor approved in 2024 for mild to moderate AD. Clinical trials (n = 1427) demonstrated significant improvements in IGA and EASI-75 after 4 weeks. Lebrikizumab : An interleukin (IL)-13-targeting monoclonal antibody approved in 2024 for moderate to severe AD. In over 1700 patients, treatment with or without topical corticosteroids led to marked improvements in clinical and patient-reported outcomes. : An interleukin (IL)-13-targeting monoclonal antibody approved in 2024 for moderate to severe AD. In over 1700 patients, treatment with or without topical corticosteroids led to marked improvements in clinical and patient-reported outcomes. Nemolizumab (with topical therapy): An IL-31 receptor inhibitor approved in 2024 for patients aged 12 years or older inadequately controlled with topical therapies. In three trials (n = 1256), nemolizumab plus topical corticosteroids (with or without topical calcineurin inhibitor) led to significant reductions in itch and improvements in EASI-75 and Dermatology Life Quality Index. Updated Treatment Algorithm The guideline includes an updated treatment algorithm to help clinicians integrate these agents into clinical practice. It emphasizes: All four newly recommended therapies are indicated with strong recommendation symbols in the updated algorithm figure. Real-World Considerations Sidbury emphasized that having multiple high-certainty options creates new opportunities but also new challenges in decision-making. 'Such choice is a lovely problem to have,' he said, but he urged clinicians to look beyond efficacy. For example, 'a patient with baseline ocular difficulties would want to be aware that IL-4/13 or IL-13 biologics can cause or exacerbate conjunctivitis,' he explained. 'Nemolizumab or a JAK inhibitor, neither of which carries ocular risk, might be a good choice. Similarly, patients with cardiovascular risk may want to avoid JAK inhibitors due to their boxed warning.' Treatment selection, he said, should be rooted in shared decision-making: 'It's important to weigh evidence alongside a patient's comorbidities, preferences, and tolerability history.' Remaining Gaps and Considerations Despite the promising data, the authors acknowledged important limitations. Most trials were short-term (≤ 24 weeks), and the long-term safety, durability of response, and comparative effectiveness of these agents remain unknown. Cost is another factor. The authors noted, 'costs for the considered therapies may be prohibitive without adequate insurance coverage.' As such, they stressed the importance of a shared decision-making process that weighs efficacy, safety, and affordability. Clinical Impact and Future Directions The update is expected to have an immediate impact in clinical settings. 'Atopic dermatitis care has long been an 'off-label' affair,' Sidbury said. 'Prior to 2017, the only FDA-approved systemic therapy for AD was systemic steroids. Since then, we've seen numerous novel topical and systemic therapies approved with many more on the way. Better evidence plus more choices equals improved outcomes.' Still, more research is needed. Sidbury pointed to the importance of identifying which therapies may work best for specific patient subtypes — by age, race, gender, or AD phenotype. 'We don't know yet, but the answer is likely yes. This gets at personalized medicine — and that's where we're headed,' he said, noting that future treatment may be guided by inflammatory signatures or genotyping. While this focused update offers valuable clarity on incorporating new treatment options for adult AD, further research is needed, according to the authors. The workgroup called for real-world data, head-to-head trials, and longer-term outcome studies. The authors also noted pediatric guideline updates are expected in a future publication. This study was funded in total by internal funds from the American Academy of Dermatology. Sidbury disclosed he serves as an advisory board member for Pfizer, receiving honoraria; as a principal investigator for Regeneron, receiving grants and research funding; as an investigator for Brickell Biotech, and Galderma USA, receiving grants and research funding; and as a consultant for Galderma Global and Microes, receiving fees or no compensation. Other authors reported having financial disclosures with many pharmaceutical companies. : Biologics, JAK inhibitors, and immunosuppressants remain key choices for refractory disease.

US and China sign trade agreement, Donald Trump says
US and China sign trade agreement, Donald Trump says

Yahoo

timean hour ago

  • Yahoo

US and China sign trade agreement, Donald Trump says

The US and China have signed an agreement on trade, President Donald Trump said, adding he expects to soon have a deal with India. Commerce Secretary Howard Lutnick told Bloomberg TV that the deal was signed earlier this week. Neither Mr Lutnick nor Mr Trump provided any details about the agreement. 'We just signed with China the other day,' Mr Trump said late on Thursday. Mr Lutnick said the deal was 'signed and sealed' two days earlier. It follows initial talks in Geneva in early May that led both sides to postpone massive tariff hikes that were threatening to freeze much trade between the two countries. Later talks in London set a framework for negotiations and the deal mentioned by Mr Trump appeared to formalise that agreement. Mr Lutnick said: 'The president likes to close these deals himself. He's the dealmaker. We're going to have deal after deal.' China has not confirmed any new agreements, but it announced earlier this week that it was speeding up approvals of exports of rare earths, materials used in high-tech products such as electric vehicles. Beijing's limits on exports of rare earths have been a key point of contention. The Chinese Commerce Ministry said on Thursday that Beijing was accelerating a review of export licence applications for rare earths and had approved 'a certain number of compliant applications'.

US and China sign trade agreement, Donald Trump says
US and China sign trade agreement, Donald Trump says

Yahoo

timean hour ago

  • Yahoo

US and China sign trade agreement, Donald Trump says

The US and China have signed an agreement on trade, President Donald Trump said, adding he expects to soon have a deal with India. Commerce Secretary Howard Lutnick told Bloomberg TV that the deal was signed earlier this week. Neither Mr Lutnick nor Mr Trump provided any details about the agreement. 'We just signed with China the other day,' Mr Trump said late on Thursday. Mr Lutnick said the deal was 'signed and sealed' two days earlier. It follows initial talks in Geneva in early May that led both sides to postpone massive tariff hikes that were threatening to freeze much trade between the two countries. Later talks in London set a framework for negotiations and the deal mentioned by Mr Trump appeared to formalise that agreement. Mr Lutnick said: 'The president likes to close these deals himself. He's the dealmaker. We're going to have deal after deal.' China has not confirmed any new agreements, but it announced earlier this week that it was speeding up approvals of exports of rare earths, materials used in high-tech products such as electric vehicles. Beijing's limits on exports of rare earths have been a key point of contention. The Chinese Commerce Ministry said on Thursday that Beijing was accelerating a review of export licence applications for rare earths and had approved 'a certain number of compliant applications'.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store